(CercleFinance.com) – Adocia climbs 6% after the announcement by the biopharmaceutical company of a first subject treated with BioChaperone Combo in the CT046 clinical trial, one of three studies funded by Tonghua Dongbao and conducted by Adocia in Germany.
CT046 evaluates the pharmacodynamics of BioChaperone Combo in comparison to Humalog Mix25 and simultaneous injections of Humalog and Lantus in healthy Chinese volunteers. Preliminary results are expected in the first quarter of 2023.
According to the license agreement with Tonghua Dongbao, Adocia received an upfront payment of $40 million and is eligible for milestone payments of up to $50 million, as well as double-digit royalties on future sales of the product. in China.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
